Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1985-06-27
1987-05-12
Brown, Johnnie R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514369, 514562, A61K 31425, A61K 3123
Patent
active
046650822
ABSTRACT:
L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.
REFERENCES:
patent: 3974031 (1976-08-01), Yamada et al.
patent: 4006057 (1977-02-01), Sano et al.
Kaneko et al., Bull. Chem. Soc., 37: 242-244, 1964.
PDR, 34th ed, 1980, pp. 1238-1241 and 1730-1732.
Meister Alton
Williamson Joanne M.
Brown Johnnie R.
Cornell Research Foundation
Rollins Jr. John W.
LandOfFree
Cysteine delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cysteine delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cysteine delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1802660